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Abstract
PV1 is an endothelial-specific protein with structural roles in the formation of diaphragms in endothelial cells of normal vessels. PV1 is also
highly expressed on endothelial cells of many solid tumours. On the basis of in vitro data, PV1 is thought to actively participate in angiogenesis.
To test whether or not PV1 has a function in tumour angiogenesis and in tumour growth in vivo, we have treated pancreatic tumour-bearing
mice by single-dose intratumoural delivery of lentiviruses encoding for two different shRNAs targeting murine PV1. We find that PV1 down-reg-
ulation by shRNAs inhibits the growth of established tumours derived from two different human pancreatic adenocarcinoma cell lines (AsPC-1
and BxPC-3). The effect observed is because of down-regulation of PV1 in the tumour endothelial cells of host origin, PV1 being specifically
expressed in tumour vascular endothelial cells and not in cancer or other stromal cells. There are no differences in vascular density of tumours
treated or not with PV1 shRNA, and gain and loss of function of PV1 in endothelial cells does not modify either their proliferation or migration,
suggesting that tumour angiogenesis is not impaired. Together, our data argue that down-regulation of PV1 in tumour endothelial cells results
in the inhibition of tumour growth via a mechanism different from inhibiting angiogenesis.
Keywords: angiogenesis fenestrae vesiculo-vacuolar organelles caveolae pancreatic cancer transendothelial
channels tumour microenvironment
Introduction
The vertebrate gene Plasmalemmal Vesicle Associated Protein
(PLVAP) encodes for PV1, a 60kd, single span, type II integral mem-
brane N-glycosylated protein [1–3]. PLVAP/PV1 expression is
restricted to a subset of normal microvascular endothelial cells (ECs)
and, in adult organisms, PV1 is not expressed in the ECs of all large
vessels with the exception of the endocardium lining the heart cham-
bers [1, 3–5]. In the ECs of normal capillaries of selected organs, PV1
is essential for the formation of the stomatal diaphragms of caveolae
and the diaphragms of fenestrae, transendothelial channels and vesi-
culo-vacuolar organelles [2, 4, 6–8]. Formation of the diaphragms
seems to be the only cellular function of PV1 [9].
Endothelial diaphragms are present in ECs of tumour vessels
undergoing angiogenesis (reviewed in [10]) and PV1 was reported
to be highly expressed in the ECs of human solid tumours, pan-
creatic cancer included [11–14] [15]. PV1 expression on tumour
ECs was known for more than two decades, through data obtained
with the PAL-E and MECA32 monoclonal antibodies (mAb), shown
recently to bind to human and mouse PV1 respectively [16, 17]
(reviewed in [10]). In vitro data suggest that PV1 plays an active
role in pathological angiogenesis by facilitating human EC tube for-
mation in Matrigel [11, 12] and EC migration induced by angio-
genic growth factors such as VEGF and HGF[11–13, 15, 18].
However, the usefulness of PV1 as a novel anti-cancer therapeutic
target is unclear [12, 19].
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Besides its structural role and postulated roles in cell migration
and angiogenesis, PV1 may also have a role in inflammation [10,
17]. PV1 blockade in mice using anti-PV1 antibodies results in
obvious impairment of recruitment of neutrophils and macrophages
at inflammation sites [17]. PV1 down-regulation by siRNA in
TNFa-activated ECs in vitro inhibits diapedesis of leucocytes with-
out affecting their adhesion to and rolling on activated ECs under
flow [17].
Pancreatic ductal adenocarcinoma (PDAC) ranks fourth among
cancers as a cause of death in the United States and Europe with a
median survival of 6 months [20]. Five-year survival is <5% and is
limited to stage I and II patients who can benefit from pancreas resec-
tion in combination with chemotherapy and radiotherapy [21]. Late
stage (III and IV) unresectable PDAC patients have access only to pal-
liative chemotherapy, yielding a median survival rate of 6–11 months
[22, 23]. So far, all PDAC therapies are short-lived and associated
with significant toxicities. Thus, pancreatic cancer patients are prime
candidates for the benefit of synergistic adjuvant therapies to increase
efficacy and/or manage toxicity.
To evaluate whether or not PV1 plays a role in angiogenesis
in vivo and the potential of PV1 as a therapeutic target in PDAC
treatment, we first tested its role in tumour growth in two different
xenograft models of PDAC. We show that PV1 down-regulation by
a single intratumoural delivery of PV1shRNA using lentiviruses
results in reduced tumour growth in these two models. Because of
the sequence mismatch between human and mouse PV1, we show
that this effect is clearly the result of PV1 down-regulation in
tumour stroma, which is of mouse origin. Moreover, in both
tumours, PV1 is expressed only in ECs of tumour vessels and not
expressed in tumour or stromal cells at protein or mRNA level.
Taken together, these data argue that PV1 expression in tumour
ECs is required for tumour growth in vivo. In addition, we show
that deletion of PV1 in tumour ECs may not result in decreased
tumour angiogenesis implicating additional mechanisms in PV1-pro-
moted tumour growth.
Materials and methods
Materials
All general reagents were from Thermo-Fisher (Pittsburgh, PA, USA),
unless otherwise stated.
Antibodies
Rat anti-mouse CD31 (PECAM-1) clone MEC13.3, unlabeled or conju-
gated to APC, was from BioLegend (San Diego, CA, USA); Mouse
anti-b-actin mAb (AC40) from Sigma-Aldrich (St. Louis, MO, USA);
Biotinylated rabbit anti-mouse IgG from Vector Laboratories (Burlin-
game, CA, USA); HRP-conjugated goat anti-rat IgG-HRP, and goat
anti-mouse IgG-HRP from Biodesign (Kennebunk, ME, USA); Goat anti-
chicken IgG-Alexa 568 and Alexa 647, (Fab)2 fragment from Invitrogen
(Eugene, OR, USA). Rat anti-mouse PV-1 mAb clone MECA-32 mAb
[9] and chicken anti-human PV1C pAb [6] were as previously
described.
Primary antibody labelling with fluorophores
Affinity purified primary antibodies, rat anti-mouse PV-1 mAb clone
MECA-32 were labelled with Alexa 568 or 647 fluorophores (Molecular
Probes; Invitrogen), as per manufacturer’s instructions.
Cells and cell culture
Mouse lung endothelial cells (MLEC) isolated from lungs of wild-type
mice or Cav1-knockout mice (MLEC-Cav1KO), and immortalized with
polyoma middle T antigen, and flow sorted for CD31 and PV1 expres-
sion, are described before [9]. MLEC were cultured on plastic in MLEC
growth medium consisting of a modified endothelial growth medium 2
(EGM2) (Lonza, Walkersville, MD, USA) formulation, from which the
serum coming with the kit was omitted and replaced with heat-inacti-
vated foetal bovine serum (FBS) (Hyclone, Logan, UT, USA) to 15%
final concentration. The formulation was also supplemented with
100 lg/ml of each penicillin, streptomycin and glutamine (Invitrogen,
Carlsbad, CA, USA), as described [9]. Bovine aortic (BAEC), human
umbilical vein (HUVEC) and human lung microvascular (HLMVEC) endo-
thelial cells were obtained from Lonza and were cultured in EGM2 or
EGM-2MV medium, respectively. The MECA-32 hybridoma (developed
by the laboratory of E. Butcher [24] at Stanford University) was
obtained from the Developmental Studies Hybridoma Bank (Iowa City,
IA, USA).
AsPC-1 and BxPC-3 human pancreatic cancer cell lines, obtained from
ATCC (Manassas, VA, USA), were grown in RPMI (Mediatech Inc., Hern-
don, VA, USA), with 10% FBS (Omega Scientific, Tarzana, CA, USA),
100 U/ml penicillin and 100 lg/ml streptomycin (complete medium).
PV1 siRNA sequences
PV1 siRNA-1, -2, -3, -4 (84094: PLVAP) were obtained from Dharmacon
(Lafayette, CO, USA). The PV1 siRNA-5 duplex (ID85339; Ambion, Aus-
tin, TX, USA) [8] and Luciferase negative control siRNA [25] were previ-
ously reported.
PV1-knockdown effectiveness was evaluated in MLEC transfected
with Oligofectamine (Invitrogen) in EBM2 culture medium lacking FBS
and antibiotics, as per manufacturer’s instructions. siRNAs were used at
a final concentration of 5 nM and PV1 knockdown assessed 24, 72 and
96 h after transfection, using Western blotting with anti-PV-1 mAb
MECA32. PV1-shRNA sequences are described in Table 1 and were
designed as in [26].
Lentivirus production and EC infection
Oligonucleotides corresponding to the short hairpin RNA (shRNA) sequence
of interest were annealed and cloned into the lentivirus vector, pLentiLox 3.7
(pll3.7) [26] (Addgene, Cambridge, MA, USA). Virus stocks were prepared
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by co-transfecting pll3.7 with three packaging plasmids pMDLg/pRRE, CMV-
VSVG and RSV-Rev, (Addgene) into 293T cells [25, 26].
Mouse lung endothelial cells were incubated (4 hrs) with lentiviruses
encoding for PV1shRNA or controls (empty virus, shLuc) at 1 and 10
MOI, with or without 8 lg/ml polybrene in infection medium (EBM-2),
followed by incubation (24–48 hrs) with MLEC growth medium; infectiv-
ity was measured by flow cytometry using GFP expression as readout.
The ability of pll3.7-based lentiviruses to infect AsPC-1 and BxPC-3
tumour cells was already demonstrated [25].
PV1-shRNA validation – immunofluorescence on
cells and confocal microscopy
Mouse lung endothelial cells were infected with lentiviruses encoding
for shLuc, shPV1-1 and shPV1-5 at an MOI = 0.1 and allowed to
express shRNA for 48 hrs. Cells were labelled live (30 min., 10°C,
EBM2 + 1% BSA) with fluorescent anti-PV1 (1.5 lg/ml), rinsed (39,
RT) in PBS containing calcium and magnesium (PBS-CM) and chased
(37°C, MLEC growth medium), rinsed (39, RT) in PBS-CM, fixed
(10 min., RT) in 4% paraformaldehyde in PBS-CM, rinsed again in PBS-
CM, mounted in PermaFluor and examined by confocal fluorescence
microscopy using a Zeiss 510 Meta confocal system (Carl Zeiss, Thorn-
wood, NY, USA). Image stacks were acquired with the pinhole set at 1
Airy unit and transformed through the maximum-intensity projection
function to obtain global images of the cells using ImageJ software
(NIH, Bethesda, MD, USA).
Flow cytometry
Labelled cells were analysed using a FacsCalibur or a CANTO flow
cytometer controlled by either CellQuest or DIVA software respectively
(BD Biosciences, San Diego, CA, USA). Data analysis was carried out
using FlowJo 9.4 software (Tree Star, Ashland, OR, USA). Each
experiment had four replicates per time-point and was repeated three
times. Median fluorescence from at least 5000 live cells was calculated
in each sample. Statistical significance was calculated using Student’s
t-test.
Generation of stable MLEC cell lines expressing
PV1shRNA
Mouse lung endothelial cells were infected with a low (0.1–0.5) MOI of
lentiviruses encoding for PV1shRNA or controls (empty virus, shLuc) in
presence of 8 lg/ml polybrene in infection medium, allowed to express
the shRNAs for 48 hrs when the cells were sorted based on GFP
expression. Transduction efficiency in these conditions was ~1–5% and
purposely designed to limit the number of multiple lentiviral integrations
in the genome. The cell populations obtained were labelled MLEC-
shPV1-1, -2, -4, -5, MLEC-shLuc MLEC-EV (empty vector).
RNA isolation
Total RNA was isolated using RNAeasy kit (Qiagen, Valencia, CA, USA)
and quality controlled using Bioanalyzer (Agilent/Stratagene, Santa Clara,
CA, USA) and NanoDrop (Thermo-Fisher).
Real-time quantitative PCR
Quantitative real-time PCR was performed as before [9], using the Gene
Expression Assays mouse PV1 (Mm00453379_m1), mouse Actin B
(Mm00607939_s1), human PV1 (Hs00229941_m1), human Actin B
(Hs03023880_g1) (Applied Biosystems, Foster City, CA, USA). Reactions
were performed in triplicate, utilizing cDNA corresponding to 10 ng RNA.
Data were analysed on the basis of the relative expression method with
the formula 2DDCT, where DDCT = DCT (sample)  DCT (calibra-
tor = average CT values of all samples), and DCT is the CT of the house-
keeping gene [beta-Actin] subtracted from the CT of the target gene.
Table 1 PV1-shRNA sequences used for insertion in lentiviruses
Gene targeted Strand shRNA sequence
Luciferase sense* 5′–TCTTACGCTGAGTACTTCGATTCAAGAGATCGAAGTACTCAGCGTAAGTTTTTTC–3′
antisense 5′–TCGAGAAAAAACTTACGCTGAGTACTTCGATCTCTTGAATCGAAGTACTCAGCGTAAGA–3′
PV1-1 sense 5′–TGCGAGCTGGAGGCGCGTAATTCAAGAGATTACGCGCCTCCAGCTCGCTTTTTTC–3′
mouse 1080-1099 antisense 5′–TCGAGAAAAAAGCGAGCTGGAGGCGCGTAATCTCTTGAATTACGCGCCTCCAGCTCGCA–3′
PV1-2 sense 5′–TGAGGTGGATGTGCGCATTATTCAAGAGATAATGCGCACATCCACCTCTTTTTTC–3′
mouse 1124-1142 antisense 5′-TCGAGAAAAAAGAGGTGGATGTGCGCATTATCTCTTGAATAATGCGCACATCCACCTCA-3′
PV1-4 sense 5′–TAGGAGAAGTTCCAGGCGGATTCAAGAGATCCGCCTGGAACTTCTCCTTTTTTTC–3′
mouse 690-708 antisense 5′ TCGAGAAAAAAAGGAGAAGTTCCAGGCGGATCTCTTGAATCCGCCTGGAACTTCTCCTA-3′
PV1-5 sense 5′–TGGAATTCAAGAAAAGGATCTTCAAGAGAGATCCTTTTCTTGAATTCCTTTTTTC–3′
mouse 1258-1276 antisense 5′-TCGAGAAAAAAGGAATTCAAGAAAAGGATCTCTCTTGAAGATCCTTTTCTTGAATTCCA-3′
*siRNA sequences used as template are in bold.
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Evaluation of cell-surface PV1 levels by flow
cytometry
Adherent MLEC stably expressing different shRNAs were labelled
(30 min., 4°C) live with 1.5 lg/ml MECA-32-Alexa 647 mAb in MLEC
growth medium, rinsed (39, RT) in PBS and non-enzymatically
detached using EDTA (Cell Dissociation Solution; Sigma-Aldrich). Cells
were then mixed with an equal volume of 1% BSA in PBS, and kept on
ice in the dark until examined using flow cytometry.
Western blotting
Equal amounts (20 lg/lane) of MLEC proteins were immunoblotted with
MECA-32 and mouse anti- b-actin monoclonal antibody (clone AC40),
as described. [9]. Signal quantization by densitometry on TIFF files was
carried out using GelEval v1.35 software (FrogDance, Dundee, UK).
Pancreatic tumour xenograft model
Female athymic mice (Nu/Nu, Charles River) were injected subcutane-
ously into the dorsal flank area with 1 9 106 of either ASPC-1 or
B9PC-3 cells. For each cell type, the mice were divided ran-
domly into four equal groups of EIGHT mice to be left untreated
or injected with shPV1-1-LV, shPV1-5-LV or shLuc-LV. Once
tumours reached a volume of 50 mm3 (8–10 days after injec-
tion of the cells), they were injected with 4.107 viral particles in
50 ll of OptiMem (Invitrogen). Tumour diameters were mea-
sured every 3 days. Tumour volumes were calculated as p/
4 9 width 9 height 9 length of the tumour. Experiments were
terminated when the tumour diameter reached 15 mm following
the procedures approved by the Dartmouth College IACUC.
Statistics on tumour growth
Data were analysed using ANOVA and Tukey HSD test for parametric data,
or the Kruskall and Wallis test for non-parametric data using the Dunn-
Benferroni test for multiple comparisons (VassarStats website).
P < 0.05 was taken as the level of significance.
Colocalization of PV1 and CD31 in tumour
samples by confocal microscopy
AsPC-1 and BxPC-3 tumours were induced as described and allowed to
grow for 21 days. One hr before harvesting, mice were injected via the
tail vein with 10 mg/kg Dark Red Fluorescent (660⁄680) FluoSpheres® in
PBS (Molecular Probes/Invitrogen, Cat# F8789) to label the intravascular
space. The mice were killed with CO2, tumours harvested unfixed, embed-
ded in optimal cutting temperature compound (OCT). Co-immunofluores-
cence experiments on methanol fixed 10 lm thick sections were
performed with 1.5 lg/ml of Alexa 647-coupled MECA-32 mAb and
Alexa488-coupled rat anti-CD31 MEC13.3 mAb and examined by confocal
fluorescence microscopy using a Zeiss 510 Meta confocal system. The
controls consisted of non-immune rat IgG2a (clone 2A3) labelled with
Alexa 647 or 488. Choice of fluorophores ensured lack of spectral overlap
between the labels to virtually eliminate co-localization artefacts.
Tumour vascular area density
Tumours processed as described above were stained with a rat anti-CD31
mAb (clone MEC13.3) (BD Biosciences) using a Vectastain ABC Peroxidase
kit (Vector Laboratories). Sections were examined using an Olympus BX-61
upright microscope equipped with an Olympus DP70 camera.
For quantitative morphometric analysis of CD31 staining in tumour
samples, 10 random fields/slide at 209 magnification were quantified for
DAB signal using Image-Pro Plus program (Version 7.0; Media Cybernet-
ics, Silver Spring, MD, USA). Three tumours per group were analysed.
Vascular area density [27, 28] was calculated as the ratio of CD31 posi-
tive pixels to the total area of the image, as described before [25].
Cell proliferation assays
To assess doubling time, cells were seeded in six well plates in triplicate
at a density of 104 cells/well and the doubling time was calculated over
5 days. Every 24 hrs, cell numbers were determined by counting the cells
using a haemocytometer. The experiments were repeated twice.
To assess cell proliferation based on DNA content, we employed an
established assay [29, 30]. Briefly, MLEC were seeded at 1000 cell/well
in 96-well plates (n = 8 wells per each time-point per genotype), cul-
tured in full growth medium and collected every day for 7 days. Each
day the wells were briefly rinsed in PBS, and the cells frozen until the
last time-point was collected. Cells were lysed by osmotic shock with
low (19) strength SSC and then incubated with 1 mg/ml Hoechst
33258 (Enzo Life Sciences, Farmingdale, NY, USA). The signal
was quantitated by spectrophotometry using a Synergy HT plate reader
(BioTek, Winooski, VT, USA).
Adenovirus constructs and transduction
Adenoviral AdEasy-1 system (Agilent/Stratagene) was used to generate
adenoviruses expressing human PV1-3xHA (AdPV1HA). Briefly, the
sequence coding for human PV1-3xHA was PCR amplified, inserted into
the multiple cloning site of the pShuttle vector and the resulting con-
struct was recombined with pAdEasy-1 vector by co-transfection in the
BJ5183 E. coli strain (Agilent/Stratagene). Positive clones were linear-
ized with Pac I restriction enzyme and transfected into 293 cells for
Adenovirus production using the CsCl2 density gradient method or the
VivaPure AdenoPACK kits (VivaScience, Sartorius, Germany).
BAECs and HUVECs were transduced (4–6 hrs, 37°C) with adenovi-
ruses at an MOI of 10 PFUs/cell for AdGFP or 50–200 viral particles/cell
for AdNull and AdPV1HA in EBM2 supplemented with 2% FBS, cells
were rinsed twice in EGM2 and incubated (24 hrs, 37°C) in growth
medium. The cells were routinely used 24 hrs after infection. Empty
adenovirus (AdNull) or adenovirus encoding GFP (AdGFP) at the same
MOI were used as controls.
Expression of PV1-HA was determined in HUVEC or BAEC trans-
duced in 100 mm dishes with an adenoviral MOI of 1. Twenty-four hrs
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after transduction, the cells were processed for Western blotting, as
described above for MLEC, using 25 lg of total protein per well and
using chicken anti-human PV1C pAb.
Endothelial cell migration assays
For scratch-wound assay, cells were grown to confluence in triplicate in
six well plates, the monolayer was scratched in five different places
using a pipette tip and cell debris removed by rinsing the cells with
medium. Images of the cells were acquired at 2, 4, 8, 12 and 20 hrs
using a Leica DMIL inverted microscope equipped with a 109 phase
contrast objective and a QImaging 12-bit CCD camera, and analysed
with ImageJ. Fifteen images per well were acquired at each time-point.
Cell migration was quantified by determining the area of the wound at
noted time-points at predetermined sites.
Electric cell-substrate impedance sensing (ECIS) automated cell-
migration assay was performed on an ECIS system (Applied BioPhysics)
equipped with a “wound healing module” and using 8-chambered gold-
plated electrode arrays (8W10E). Cells (5 9 104/well) were plated on
sterile 8W10E electrodes pre-coated with 0.1% porcine gelatin (collagen
I), grown to full confluence and transduced with adenoviruses. Immedi-
ately after adenoviral transduction, the electrode arrays were mounted
on the ECIS system within an incubator (37°C, 5% CO2) and connected
to its recorder device. The cell monolayer was wounded by electric
pulses, the medium changed and the transendothelial electrical resis-
tance, an index of endothelial cell barrier function, was measured in real
time and recorded for 50 hrs in 5-min. intervals.
Results
PV1 down-regulation by lentiviral-encoded
shRNA
Small interfering siRNA sequences directed against mouse PV1, pre-
viously reported [6, 8] or designed de novo, were transfected in
MLEC and PV1 knockdown determined by immunoblotting. As all the
PV1 siRNAs were able to down-regulate PV1 (data not shown), these
sequences were used to design the shRNA sequence to be introduced
into the pll3.7 vector for lentivirus (LV) generation. The lentiviral vec-
tor also encodes for the green fluorescent protein (GFP) for ease of
identification of transduced cells. The siRNA and shRNA sequences
used are shown in Table 1.
We first determined that all LVs generated were able to infect
mouse ECs at low MOI, as shown by flow cytometric quantification of
GFP-expressing cells (Fig. 1A) or using fluorescence confocal
microscopy (Fig. 1B).
Next, the effectiveness of PV1 down-regulation in MLEC stably
transduced with shRNA-LVs targeting PV1 or luciferase (shLuc-LV)
was tested by multiple complementary approaches. We chose to
study long-term, stable expression of shRNAs, as it is more relevant
to the in vivo experimental approach. According to real-time PCR
(not shown) and Western blotting results (Fig. 1C), total cellular
levels of PV1 were decreased by more than 70% for all the
PV1-shRNA-expressing cell lines. As PV1 function occurs at the cell
surface [9], we determined the effect of different shRNAs on plasma
membrane levels of PV1 protein. We show using confocal microscopy
(Fig. 1B) and flow cytometry (Fig. 1E) that all mouse PV1-shRNA-
LVs efficiently silenced PV1 protein expression at the cell surface by
more than 80% compared to non-infected or shLuc-LV-transduced
MLEC. The lack of effect of shLuc control LV on PV1 protein levels is
shown in Figure 1E. The efficiency of shLuc-LV control virus to
decrease luciferase activity in 293 cells constitutively expressing lucif-
erase was previously validated [25]. The two most efficient mouse
shRNA-LVs, namely shPV1-1 and shPV1-5, were used in all subse-
quent experiments.
Intratumoural delivery of PV1-shRNA inhibits the
growth of established pancreatic tumours
To determine whether the LV-mediated PV1 down-regulation is able
to inhibit PDAC growth, we employed a model system consisting of
heterotopic tumours derived from two different human PDAC cell
lines (AsPC-1 and BxPC-3) grown subcutaneously in nude mice.
Following subcutaneous injections of AsPC-1 or BxPC-3 cells,
tumour growth was monitored and mice with established tumours
(volume of 50 mm3) were enrolled in four different groups, one to be
left untreated and three treated with one injection either of shPV1-1-
LV, of shPV1-5-LV or shLuc-LV. Tumour growth was determined over
a period of several weeks. A statistically significant difference in
tumour volumes between shLuc-LV-injected tumours and shPV1-LV-
injected tumours was seen as early as 24 and 33 days following viral
injection of AsPC-1- and BxPC-3-derived tumours respectively. The
subsequent growth of all shPV1-LV-injected tumours remained signifi-
cantly attenuated. By the end of the experiment, AsPC-1 tumours that
were infected with shPV1-1-LV exhibited a 35% (P < 0.05) decrease
in volume and 65% (P < 0.05) with shPV1-5 (Fig. 2A) in comparison
with tumours infected with shLuc-LV or control tumours left
untreated. No statistically significant differences were detected
between the growth of tumours infected with shLuc-LV and control
tumours left untreated. With respect to BxPC-3, shPV1-1 inhibited
tumour growth by 57% (P < 0.01) and shPV1-5 one of 49%
(P < 0.01) (Fig. 2B). Taken together, these data demonstrate that PV1
down-regulation by two different shRNAs are able to inhibit pancreatic
tumour growth in two different human-PDAC xenograft models.
PV1 is expressed specifically in the EC of tumour
xenografts and is not expressed in tumour cells
The sequence mismatches between mouse PV1 shRNAs and human
PV1 strongly argued that tumour growth inhibition occurred via PV1
down-regulation in the tumour microenvironment (i.e. ECs, stromal
cells and tumour-infiltrating leucocytes), which is of murine origin. To
strengthen this observation, we defined the precise cellular type(s)
expressing PV1 in the AsPC-1- and BxPC-3-derived tumours.
Although PV1 is expressed in tumour ECs in many solid tumours
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Fig. 1 PV1 knockdown by lentiviral shRNA. (A) Flow cytometry analysis demonstrating the ability of each of the generated LVs to infect mouse ECs,
as demonstrated by GFP expression. The cells were incubated with a LV dose of ~0.1 MOI. The GFP-positive cells were used for sorting to generate
stable cell lines expressing the various shRNAs. (B) Laser confocal microscopy demonstrating the down-regulation of PV1 signal in cells transduced
with low MOI of shPV1-1-LV (top panels) or shPV1-5-LV (bottom panels). PV1 signal was detected with the anti-PV1 MECA-32 mAb directly cou-
pled to a fluorophore (red). Transduced cells were identified by their expression of GFP (green). The images represent maximum-intensity projec-
tions of confocal stacks encompassing all the cell thickness, acquired with a 609 objective and no zoom. Non-transduced cells serve as an internal
control for normal PV1 levels. Bars 20 lm. (C) Total cellular-PV1 protein levels in MLEC stably transduced with LVs encoding for shLuc, shPV1-1, -
2, -4 and -5. Equal amounts (20 lg/lane) of proteins were resolved by SDS-PAGE and immunoblotted with anti-PV1 and anti-actin antibodies, as
described in Methods. (D) Quantization of PV1 level on the surface of mouse ECs transduced with LVs encoding for shLuc, shPV1-1, -2, -4 and -5.
The data represent median fluorescence (n = 4, P < 0.01, error bars -stdev). (E) Examples of flow cytometry data showing PV1 levels on the sur-
face of MLEC parental (orange trace), MLEC-shLuc (green trace), MLEC-shPV1-1 (blue trace), MLEC-shLuc (red trace).
Fig. 2 Intratumoural delivery of PV1
shRNA inhibits pancreatic tumour growth.
Growth curves of AsPc-1 (A) and BxPC-3
(B) tumours either non-treated (open dia-
monds) or injected with shLuc-LV (open
squares), shPV1-1-LV (open triangles)
and shPV1-5-LV (x). (n = 8 per group,
P < 0.01, error bars – SEM).
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including pancreatic cancer, there is no previous information regard-
ing PV1 expression in AsPC-1- and BxPC-3-derived tumours. To
address this, the vascular space of tumour-bearing mice was labelled
with fluorescent microspheres, tumours harvested and sections
stained with anti-PV1 antibodies directly labelled to fluorophores. We
used the MECA-32 mAb that recognizes only mouse PV1 [24] [16],
and the anti-hPV1C pAb that specifically recognizes human PV1 [6].
In agreement with data published for other tumours [31–34], mouse-
PV1 expression was detected solely in the pancreatic tumour ECs, as
shown by its co-localization with the fluorescent microspheres as
luminal markers of the functional blood vessels (Fig. 3A and B) and
EC markers PECAM-1/CD31 (Fig. 3A and B), ICAM-2/CD102
Fig. 3 In both AsPC-1 and BxPc-3 pancreatic tumours PV1 is expressed only in tumour endothelial cells (A–B) Confocal microscopy of frozen sec-
tions from AsPC-1 pancreatic tumours grown in nude mice, with anti-PV1 (red) and anti-CD31 (green) and antibodies directly coupled to fluoro-
phores. The vascular lumen (blue) was labelled by the introduction of dark red microspheres in the circulation. In the merged field, white means
triple co-localization. Last panel in each shows nuclei stained with DAPI. (A) is a representative field showing vessels inside the tumour whereas (B)
shows vessels at the tumour periphery. Magnification 209. Bars – 20 lm. (C) Immunohistochemistry of serial frozen sections from human pancre-
atic xenograft tumours grown in nude mice, with anti-PV1 (PV1) and anti-CD31 (CD31) antibodies. The nuclei are counter stained with haematoxylin.
Bars – 20 lm. (D) PV1-mRNA levels in HLMVEC and human pancreatic tumour cell lines AsPC-1 and BxPC-3 measured by real-time quantitative
PCR. The data were obtained from triplicate samples and normalized to b-actin levels (DDCt). Bars – SEM (E) Confocal microscopy of frozen sec-
tions from AsPC-1 pancreatic tumours grown in nude mice, stained with anti-human PV1 (red) showing lack of expression of PV1 by human cancer
cells. In the same specimen, mouse PV1 (blue) is present and colocalizes with the vascular marker CD102 (green), both detected by antibodies
directly coupled to fluorophores. Magnification 209. Bars – 10 lm.
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(Fig. 3E), endoglin/CD105 and CD34 (data not shown). Similar results
were obtained by staining of serial sections with anti-PV1 mAb
MECA-32 and anti-CD31 (Fig. 3C). We also found that both AsPC-1
and BxPC-3 cells in culture lack expression of PV1 mRNA as shown
by real-time PCR (Fig. 3D). Positive controls for real-time PCR were
human lung microvascular endothelial cells (HLMVEC) and HLMVEC
treated with phorbol myristate acetate, expressing low and high levels
of PV1 respectively [6]. As a control for differences between cancer
cells in culture and tumours in vivo, tumour sections were also
probed with human PV1 antibodies. No expression of human PV1
was detected in the AsPC-1 or BxPC-3 tumour sections.
Thus, in both AsPC-1 and BxPC-3 tumours, PV1 is specifically
expressed in the tumour ECs and not in the tumour cells per se, in
good agreement with data in the literature obtained in other tumours.
PV1 down-regulation does not affect vascular
density of tumours
Next, we investigated whether the tumour growth inhibition induced
by PV1 down-regulation is because of inhibition of tumour angiogene-
sis. Morphometric analyses of tumour sections stained with antibod-
ies against vascular markers such as CD31 were performed to
determine the vascular area density, which is a measure of angiogen-
esis [35]. Representative images of CD31 staining are shown in Fig-
ure 4A. Quantitation data show that there are no statistically
significant differences in vascular area density between the control
and PV1 shRNAs-treated AsPC-1- and BxPC-3-derived tumours
(Fig. 4B).
This result raises doubts that tumour growth inhibition was the
result of decreased angiogenesis in this model system suggesting
that endothelial PV1 is necessary for tumour growth via other mecha-
nisms than promoting angiogenesis.
PV1 down-regulation does not modify endothelial
cell proliferation and migration in vitro
Angiogenesis, defined as the formation of new vessels from pre-exist-
ing ones is based on the ability of ECs to proliferate and migrate [36]
[37]. To strengthen the above observations we have next investigated
whether the modulation of PV1 expression level influences any of
these EC cellular functions in vitro. To determine the effect of PV1
gain of function, we used ECs that do not express PV1 (such as HU-
VEC and BAEC) either not transduced or transduced with AdPV1HA,
AdNull or AdGFP. To determine the effect of PV1 loss of function we
have compared MLEC, which constitutively express PV1 and with
MLEC stably expressing different shRNAs.
De novo expression of PV1 does not modify proliferation rate of
HUVEC (Fig. 5A) or BAEC (not shown), as determined using an assay
measuring DNA content. Controls consisted of non-transduced cells
and cells transduced with the same MOI of AdGFP or AdNull. Flow cy-
tometric analyses of PV1 and GFP expression shows that the cells are
efficiently transduced by the adenovirus (Fig. 5B). Reciprocally, in
MLEC that constitutively express PV1, PV1 down-regulation by trans-
duction with lentiviruses encoding PV1 shRNAs does not modify PV1
proliferation, as measured by population doubling time (Fig. 5C) or
DNA content (Fig. 5D).
Cell migration was assessed using wound assays by either the
classical scratch method or by ECIS (electric cell impedance sensing).
By the two methods, we found no statistically significant differences
between ECs expressing PV1 and those that did not (Fig. 5E and F).
Taken together, these data argued that either PV1 overexpression or
PV1 down-regulation did not modify EC proliferation and migration.
Discussion
PV1 is an endothelial protein with important roles in formation of dia-
phragms of caveolae, fenestrae, transendothelial channels and, possi-
bly, vesiculo-vacuolar organelles. The diaphragms are structures with
unknown functions. PV1 is specifically expressed on normal ECs in a
subset of vascular beds. PV1 is also specifically expressed in ECs of
many human and mouse tumours, pancreatic cancer included. The
strong expression of PV1 in the tumour ECs raises the question as to
its function, if any, especially related to tumour initiation and progres-
sion.
Fig. 4 Down-regulation of PV1 does not decrease tumour vascular den-
sity (A) Immunohistochemistry with anti-CD31 antibodies of AsPC-1
(left panels) or BxPC-3 (right panels) tumours untreated (parental) or
treated with shLuc-LVs (shLuc), shPV1-1-LV (shPV1-1) and shPV1-5-
LV (shPV1-5). Bars – 20 lm. (B) Morphometric analysis of vascular
density in AsPC-1 and BxPC-3 tumours [shLuc-LVs (Luc), shPV1-1-LV
(sh1) and shPV1-5-LV (sh5)]. Error bars – SEM.
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On the basis of its specific location, PV1 was hypothesized to play
an active role in tumour angiogenesis, which is sustained by the pub-
lished in vitro data where PV1 down-regulation by siRNA was shown
to block the formation of capillary tubes by human ECs in Matrigel
and migration towards tumour-secreted angiogenic growth factors
[12]. These in vitro data, supporting a role of PV1 in EC migration,
have not yet been validated in vivo prompting us to ask this question
in a heterotopic xenograft tumour model.
As a model system, we have chosen heterotopic human tumour
xenografts in athymic nude mice treated with LV encoded PV1 shRNA
delivered by intratumoural injection. Tumours were derived from
AsPC-1 and BxPC-3 cells, two established human PDAC cell lines iso-
lated from metastatic and primary PDAC tumours, respectively. The
model is simple to execute and the intratumoural injection of lentivi-
ruses expressing various shRNAs was previously validated to be an
effective means in down-regulating target molecules in this model
[25]. Because the tumour microenvironment (i.e. tumour ECs, stro-
mal cells and tumour-infiltrating leucocytes) is all derived from the
mouse host, the model also allows the study of the down-regulation
of PV1 expressed in the stroma versus tumour cells using species-
specific shRNAs.
The salient finding of our work is the efficacy of PV1 down-regula-
tion by shRNA in inhibiting the growth of pre-existing tumours in both
PDAC models. This study demonstrates, for the first time, the
potential therapeutic effect of targeting PV1 for the treatment of
PDAC. As shown before, no inhibitory effect of the empty virus or
shLuc-LV was observed when compared to the untreated tumours,
demonstrating that tumour inhibition is not because of non-specific
effects of the LVs or the shRNA. Moreover, this also shows that shR-
NAs do not inhibit angiogenesis non-specifically, as was suggested
by other studies with targeted and non-targeted siRNAs acting via
toll-like receptor 3 (TLR3) [38, 39]. The specificity we observe could
Fig. 5 PV1 levels do not modify EC proliferation and migration (A) Proliferation of HUVEC transduced with adenoviruses encoding for PV1 (AdPV1)
or GFP (AdGFP) measured with the DNA content assay. Data were obtained from n = 8 sample replicates per condition. Error bars – SEM. (B) Flow
cytometric analysis of PV1 (left) and GFP expression (right) in HUVEC transduced with AdPV1HA (AdPV1) or AdGFP (AdGFP). Control cells were
either non-transduced or AdNull transduced HUVEC. Representative samples (of n = 4) are shown in each panel. Control cells (grey histogram),
AdGFP-transduced cells (dashed line histogram), AdPV1HA-transduced cells (solid line histogram). (C) Average doubling time of MLEC parental or
stably expressing shLuc (Luc), shPV1-1 (sh1) or shPV1-5 (sh5). Data were obtained from triplicate samples. Error bars –SEM. (D) Proliferation of
MLEC parental or stably expressing shLuc (Luc), shPV1-1 (sh1) or shPV1-5 (sh5) measured with the DNA content assay. Data were obtained from
n = 8 samples per condition. Error bars – SEM. (E–F) Migration of HUVEC transduced with adenoviruses encoding for PV1 (AdPV1) or GFP
(AdGFP), as measured by the monolayer wound assay at 8 hrs after monolayer wounding (E) or by the ECIS method (F). For the latter, the cells
were plated onto electrodes at near confluence and the monolayer allowed to mature for 44 hrs when the cells over the electrodes were eliminated
with electric pulses and the monolayer recovery was monitored for 11 hrs. The traces are representative samples. Data were obtained from n = 4
sample replicates per condition. Error bars in E) – STDEV.
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be because of the fact that in our model, shRNAs are expressed inside
the LV-infected cells and as such, may not engage TLR3. Finally, the
inhibition of tumour growth by two different PV1 shRNAs in two dif-
ferent models rules out (or makes highly unlikely) off-target effects of
individual shRNAs.
The LVs infect all cell types present in the tumour [25], therefore it
was important to demonstrate the specificity of PV1 location in these
tumours. Staining tumour sections with PV1 and various EC markers
used to detect tumour vessels, we show that PV1 is specifically
expressed in ECs and not tumour cells, as shown for many other
tumours before [10–12, 15]. We verified that tumour cells lack PV1 at
both protein and mRNA level. Most importantly, the shRNA sequences
used do not target human PV1. These data demonstrate that down-regu-
lation of endothelial PV1 is responsible for the anti-tumour effect, open-
ing the possibility to use PV1 as a therapeutic target in a broad range of
cancers, where PV1 is expressed in the vessels.
The effect of PV1 down-regulation on tumour growth can be rea-
sonably explained by the effect of either inhibition of tumour angio-
genesis resulting in decreased ratio of tumour vascular volume to
tumour tissue volume and/or impaired function of the tumour ves-
sels. We find that the vascular area counts inside and at the periphery
of the tumour were similar in both shPV1 and control-treated
tumours, suggesting that angiogenesis may not be impaired in the
PDAC models used. Although the value of density counts in measur-
ing whether angiogenesis is inhibited or not has limits, as discussed
in the past by Hlatky, et al., [40], these conclusions are supported by
the lack of effect of PV1 gain and loss of function on both EC prolifer-
ation and migration in vitro. Moreover, analysis of PV1-knockout mice
demonstrates that PV1 is not required for both vasculogenesis and
angiogenesis during mouse development, as these mice have nor-
mally formed vessels (D. Tse, S. Deharvengt, C. McGarry, D. S. Long-
necker, C. Carriere and R. V. Stan, unpublished data).
Several laboratories have demonstrated PV1 to be expressed spe-
cifically in tumour ECs and we have recently published data strongly
suggesting that, at cellular level, the function of PV1 in ECs is to form
diaphragms [9]. These diaphragms are associated with four different
EC structures, of which caveolae [41] and vesiculo-vacuolar organ-
elles [42] were previously postulated as regulating tumour growth.
Additional experiments will be needed to dissect which diaphragm on
which organelle is important.
At the vascular physiology function level, to date, PV1 was
implicated in the maintenance of basal permeability in normal ves-
sels (Tse, et al., 2012, submitted) and in the recruitment of leuco-
cytes into inflammation sites, by unknown mechanisms [17].
Tumour vessels are fenestrated in most solid cancers and are quite
disorganized and leaky; the significance of this increased leakiness
for tumour growth is under debate [43]. If we are to speculate,
the deletion of PV1 will presumably increase the permeability of
tumour vessels by deletion of the diaphragms of fenestrae, and
possibly those of VVOs. Presently, it is not obvious what conse-
quences this increased leakiness of already leaky vessels will have
on tumour growth. Moreover, data in the literature argues that
decreasing tumour vascular permeability inhibits tumour growth
[44]. Finally, PV1 promotion of diapedesis of leucocytes in inflam-
mation sites [17] raises the possibility of PV1 being important for
recruitment of tumour-infiltrating leucocytes with roles in promot-
ing tumour growth [45], which is currently under study in immu-
nocompetent models of cancer.
Finally, by far the most exciting, is the translational potential of
PV1 function to be harnessed in devising new drugs against cancer.
Here too, experiments employing disease-relevant genetically engi-
neered mouse models will be needed to further explore the role of
PV1 in tumour growth.
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